AR085501A1 - ANTICUERPO ANTI-TNF a HUMANIZADO - Google Patents

ANTICUERPO ANTI-TNF a HUMANIZADO

Info

Publication number
AR085501A1
AR085501A1 ARP120100640A ARP120100640A AR085501A1 AR 085501 A1 AR085501 A1 AR 085501A1 AR P120100640 A ARP120100640 A AR P120100640A AR P120100640 A ARP120100640 A AR P120100640A AR 085501 A1 AR085501 A1 AR 085501A1
Authority
AR
Argentina
Prior art keywords
seq
sequence
antibody
tnf
humanized anti
Prior art date
Application number
ARP120100640A
Other languages
English (en)
Spanish (es)
Original Assignee
Livzon Mabpharm Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=46757361&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=AR085501(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Livzon Mabpharm Inc filed Critical Livzon Mabpharm Inc
Publication of AR085501A1 publication Critical patent/AR085501A1/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/24—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
    • C07K16/241—Tumor Necrosis Factors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/20—Antivirals for DNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/20—Antivirals for DNA viruses
    • A61P31/22—Antivirals for DNA viruses for herpes viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P33/00—Antiparasitic agents
    • A61P33/02—Antiprotozoals, e.g. for leishmaniasis, trichomoniasis, toxoplasmosis
    • A61P33/06—Antimalarials
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/33—Crossreactivity, e.g. for species or epitope, or lack of said crossreactivity
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Engineering & Computer Science (AREA)
  • Virology (AREA)
  • Immunology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Oncology (AREA)
  • Molecular Biology (AREA)
  • Communicable Diseases (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Biotechnology (AREA)
  • Neurosurgery (AREA)
  • Pulmonology (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Transplantation (AREA)
  • AIDS & HIV (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
ARP120100640A 2011-02-28 2012-02-28 ANTICUERPO ANTI-TNF a HUMANIZADO AR085501A1 (es)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
CN201110048505 2011-02-28
CN201210026698.5A CN102675460B (zh) 2011-02-28 2012-02-07 抗肿瘤坏死因子α的人源化抗体
PCT/CN2012/071079 WO2012116595A1 (zh) 2011-02-28 2012-02-13 抗肿瘤坏死因子α的人源化抗体

Publications (1)

Publication Number Publication Date
AR085501A1 true AR085501A1 (es) 2013-10-09

Family

ID=46757361

Family Applications (1)

Application Number Title Priority Date Filing Date
ARP120100640A AR085501A1 (es) 2011-02-28 2012-02-28 ANTICUERPO ANTI-TNF a HUMANIZADO

Country Status (10)

Country Link
EP (1) EP2682405A4 (enExample)
JP (2) JP6054864B2 (enExample)
KR (1) KR101576559B1 (enExample)
CN (1) CN102675460B (enExample)
AR (1) AR085501A1 (enExample)
AU (1) AU2012222738B2 (enExample)
BR (1) BR112013021860A2 (enExample)
CA (1) CA2827799C (enExample)
RU (1) RU2549700C1 (enExample)
WO (1) WO2012116595A1 (enExample)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN103217489B (zh) 2013-01-15 2016-03-09 珠海市丽珠单抗生物技术有限公司 一种测定蛋白纯化工艺过程中样品的糖基化和末端修饰情况的方法
WO2015190439A1 (ja) * 2014-06-09 2015-12-17 株式会社カネカ 抗体に結合する低分子化合物のスクリーニング方法
CN109153718B (zh) * 2016-03-17 2022-02-08 努玛治疗有限公司 抗TNFα抗体及其功能片段
CN106279413A (zh) * 2016-08-30 2017-01-04 苏州普罗达生物科技有限公司 抗肿瘤坏死因子抗体多肽及应用
CN111153994B (zh) * 2019-12-31 2021-10-15 武汉班科生物技术股份有限公司 人肿瘤坏死因子的人源单克隆抗体
CN115819575B (zh) * 2022-08-24 2023-06-27 武汉爱博泰克生物科技有限公司 针对人肿瘤坏死因子-α的单克隆抗体
CN115710314B (zh) * 2022-09-14 2025-10-28 江苏睿源生物技术有限公司 用于检测肿瘤坏死因子-α的抗体组合及其应用

Family Cites Families (23)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3773919A (en) 1969-10-23 1973-11-20 Du Pont Polylactide-drug mixtures
US4275149A (en) 1978-11-24 1981-06-23 Syva Company Macromolecular environment control in specific receptor assays
US4318980A (en) 1978-04-10 1982-03-09 Miles Laboratories, Inc. Heterogenous specific binding assay employing a cycling reactant as label
US5179017A (en) 1980-02-25 1993-01-12 The Trustees Of Columbia University In The City Of New York Processes for inserting DNA into eucaryotic cells and for producing proteinaceous materials
US4376110A (en) 1980-08-04 1983-03-08 Hybritech, Incorporated Immunometric assays using monoclonal antibodies
US4818679A (en) 1985-02-19 1989-04-04 The Trustees Of Columbia University In The City Of New York Method for recovering mutant cells
US4737456A (en) 1985-05-09 1988-04-12 Syntex (U.S.A.) Inc. Reducing interference in ligand-receptor binding assays
DE3631229A1 (de) 1986-09-13 1988-03-24 Basf Ag Monoklonale antikoerper gegen humanen tumornekrosefaktor (tnf) und deren verwendung
GB9109645D0 (en) * 1991-05-03 1991-06-26 Celltech Ltd Recombinant antibodies
US5919452A (en) 1991-03-18 1999-07-06 New York University Methods of treating TNFα-mediated disease using chimeric anti-TNF antibodies
DE69233701T2 (de) 1991-03-18 2008-04-10 New York University Monoklonale und chimäre Antikörper spezifisch für menschlichen Tumornekrosefaktor
UA81743C2 (uk) * 2000-08-07 2008-02-11 Центокор, Инк. МОНОКЛОНАЛЬНЕ АНТИТІЛО ЛЮДИНИ, ЩО СПЕЦИФІЧНО ЗВ'ЯЗУЄТЬСЯ З ФАКТОРОМ НЕКРОЗУ ПУХЛИН АЛЬФА (ФНПα), ФАРМАЦЕВТИЧНА КОМПОЗИЦІЯ, ЩО ЙОГО МІСТИТЬ, ТА СПОСІБ ЛІКУВАННЯ РЕВМАТОЇДНОГО АРТРИТУ
WO2003042247A2 (en) * 2001-11-12 2003-05-22 Merck Patent Gmbh Modified anti-tnf alpha antibody
US20030206898A1 (en) * 2002-04-26 2003-11-06 Steven Fischkoff Use of anti-TNFalpha antibodies and another drug
CN1225479C (zh) * 2002-12-23 2005-11-02 马菁 肿瘤坏死因子抗体，其制备方法以及药物组合物
CN1255536C (zh) 2003-11-13 2006-05-10 中国人民解放军第四军医大学 高亲和力抗肿瘤坏死因子单克隆抗体的可变区基因及其制备
KR100772800B1 (ko) 2003-11-17 2007-11-01 주식회사유한양행 인간 종양괴사인자 α를 인식하는 단일클론항체의가변영역 및 이를 코딩하는 유전자
WO2006031370A2 (en) * 2004-08-19 2006-03-23 Genentech, Inc. Polypeptide variants with altered effector function
KR100971497B1 (ko) * 2004-12-29 2010-07-21 주식회사유한양행 인간 종양괴사인자-알파에 특이적으로 결합하는 인간화항체
CN101177453B (zh) * 2006-11-07 2010-09-29 旭华（上海）生物研发中心有限公司 抗人肿瘤坏死因子α的重组嵌合抗体
KR20100053607A (ko) * 2007-08-03 2010-05-20 패시트 바이오테크 코포레이션 항-ｔｗｅａｋ 수용체 항체의 치료 용도
EP2050764A1 (en) * 2007-10-15 2009-04-22 sanofi-aventis Novel polyvalent bispecific antibody format and uses thereof
PL2242773T3 (pl) * 2008-02-11 2017-11-30 Cure Tech Ltd. Przeciwciała monoklonalne do leczenia nowotworu

Also Published As

Publication number Publication date
CN102675460B (zh) 2015-08-19
JP6054864B2 (ja) 2016-12-27
KR101576559B1 (ko) 2015-12-10
JP2013539354A (ja) 2013-10-24
EP2682405A1 (en) 2014-01-08
KR20130133272A (ko) 2013-12-06
EP2682405A4 (en) 2015-06-24
WO2012116595A1 (zh) 2012-09-07
AU2012222738A1 (en) 2013-08-22
AU2012222738B2 (en) 2016-05-26
CA2827799C (en) 2017-03-21
BR112013021860A2 (pt) 2018-09-11
JP2016006052A (ja) 2016-01-14
RU2013139480A (ru) 2015-04-10
CN102675460A (zh) 2012-09-19
RU2549700C1 (ru) 2015-04-27
CA2827799A1 (en) 2012-09-07
NZ615477A (en) 2015-11-27

Similar Documents

Publication Publication Date Title
ES2564252T3 (es) Anticuerpos anti-péptido beta-amiloide N3pGlu y usos de los mismos
AR085501A1 (es) ANTICUERPO ANTI-TNF a HUMANIZADO
ES2687282T3 (es) Anticuerpos humanizados ANTI-CD134 (OX40) y sus usos
ES2620264T3 (es) Anticuerpos humanizados frente a LIV-1 y el uso de los mismos para tratar el cáncer
PE20180042A1 (es) Anticuerpos anti-ox40 y metodos de uso de los mismos
AR084141A1 (es) Anticuerpos neutralizadores anti-ccl20
AR106184A1 (es) Proteínas de unión a pd-1 y sus métodos de uso
MX341958B (es) Anticuerpos contra el il33r humano y usos de los mismos.
PE20141568A1 (es) Anticuerpos humanizados que reconocen la alfa-sinucleina
AR084315A1 (es) Anticuerpos anti-notch1
ES2621874T3 (es) Anticuerpos para MUC16 y métodos de uso de los mismos
AR096617A1 (es) Anticuerpos anti-tweakr y sus usos
PE20181054A1 (es) Anticuerpos anti-cd19 humano humanizados y metodos de utilizacion
ES2584956T3 (es) Anticuerpos anti-CD40 y usos de los mismos
ES2670621T3 (es) Anticuerpos que se unen a OX40 y sus usos
CO6430469A2 (es) Anticuerpos humanizados que se unen a cd19 y sus usos
AR098465A1 (es) ANTICUERPOS ANTI-a-SINUCLEÍNA Y MÉTODOS DE UTILIZACIÓN
PE20150002A1 (es) Anticuerpos anti-fcrn
PH12015501505B1 (en) Antibodies that bind to tl1a and their uses
CO6410312A2 (es) Moléculas de anticuerpo que tienen especificidad por humano ox40
NZ629296A (en) Humanized antibodies that recognize alpha-synuclein
PE20091024A1 (es) Anticuerpos monoclonales que se unen a anexelekto y sus usos
AR096687A1 (es) Anticuerpos anti-fcrh5
PE20141147A1 (es) Anticuerpos a pcsk9 y usos de los mismos
MX366359B (es) Anticuerpos humanizados contra la molecula de adhesion celular relacionada al antigeno carcinoembrionico 1 (ceacam1).

Legal Events

Date Code Title Description
FB Suspension of granting procedure